Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20730041 | 0.97 | CA14 (0.47) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL13784777 | 0.95 | CA14 (0.48) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL5460363 | 0.91 | CA14 (0.53) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL1028104 | 0.89 | CA14 (0.41) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL1274075 | 0.89 | CA14 (0.55) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL31324971 | 0.89 | CA14 (0.51) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL17471898 | 0.88 | CA14 (0.48) | CA14HDAC6HDAC1HDAC2CA12 | |
| Hydrochloric Acid SCHEMBL3451895 | 0.87 | CA14 (0.40) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL10226292 | 0.87 | CA14 (0.54) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL10226299 | 0.87 | CA14 (0.54) | CA14HDAC6HDAC1HDAC2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4274569-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-116635028-A | Modulators of c-MYC mRNA translation and their use in the treatment of cancer | 艾尼莫生物科技公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20220411396-A1 | TRIOXOLANE AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-12-29 | — | — | US | disclosed |
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-11-24 | — | — | US | disclosed |
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-11-24 | — | — | US | disclosed |
| WO-2022150316-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022150316-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| US-11318132-B2 | Diversion-resistant opioid formulations | ELYSIUM THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| EP-3305784-B1 | HAPTENS OF QUETIAPINE FOR USE IN IMMUNOASSAYS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-12 | — | — | EP | disclosed |
| US-20200113893-A1 | DIVERSION-RESISTANT OPIOID FORMULATIONS | ELYSIUM THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| US-10314839-B2 | Diversion-resistant opioid formulations | ELYSIUM THERAPEUTICS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| EP-2887952-B1 | ANTIBODIES TO OLANZAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-15 | — | — | EP | disclosed |
| US-20160136153-A1 | DIVERSION-RESISTANT OPIOID FORMULATIONS | ELYSIUM THERAPEUTICS, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20090318424-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318424-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| WO-2007147109-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| EP-1468688-A2 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | Auckland Uniservices Limited (NZ) | 2004-10-20 | — | — | EP | disclosed |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-09-30 | — | — | US | disclosed |
| US-6063791-A | N-benzenesulfonyl-L-proline derivatives, method for preparing and therapeutic use | FOURNIER INDUSTRIE ET SANTE (FR) | 2000-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | CA14 4579/4885HDAC6 1919/4885HDAC1 2726/4885 |
| US-20220411396-A1 | TRIOXOLANE AGENTS | ABCB4, SLC10A1, SLC10A2 | CA14 1532/4885HDAC6 3841/4885HDAC1 3955/4885 |
| US-20160136153-A1 | DIVERSION-RESISTANT OPIOID FORMULATIONS | OPRL1, OPRK1, OPRM1 | CA14 3595/4885HDAC6 342/4885HDAC1 1116/4885 |
| US-11318132-B2 | Diversion-resistant opioid formulations | OPRL1, OPRK1, OPRM1 | CA14 3595/4885HDAC6 342/4885HDAC1 1116/4885 |
| US-20200113893-A1 | DIVERSION-RESISTANT OPIOID FORMULATIONS | OPRL1, OPRK1, OPRM1 | CA14 3595/4885HDAC6 342/4885HDAC1 1116/4885 |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | NPM1, DUOX1, NOX5 | CA14 1811/4885HDAC6 649/4885HDAC1 389/4885 |
| US-10314839-B2 | Diversion-resistant opioid formulations | OPRL1, OPRK1, OPRM1 | CA14 3595/4885HDAC6 342/4885HDAC1 1116/4885 |
| US-20090318424-A1 | NOVEL COMPOUNDS | MAPKAPK2, MAPKAPK3, CDC42BPB | CA14 4675/4885HDAC6 635/4885HDAC1 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.